In historic first, FDA approves Novartis CAR-T therapy
Biopharama | August 30, 2017
The Food and Drug Administration on Wednesday approved the first CAR-T therapy, ushering in a new approach to treating cancer in a landmark decision for the rapidly advancing field of cell therapy. Treatment with the therapy, developed by Swiss pharma Novartis AG, led to remarkable results in children with an aggressive form of leukemia resistant to other drugs.